Key result
Oral disopyramide prolonged the shortest RR interval during atrial fibrillation from 169 to 248 msec (P<0.0001) in patients with Wolff-Parkinson-White syndrome.
Why the study?
Does disopyramide phosphate improve electrophysiologic parameters in patients with Wolff-Parkinson-White syndrome?
Population
12 patients with Wolff-Parkinson-White syndrome
Comparison
Disopyramide phosphate vs Control period
Design
Case_series
Follow-up
3 days for electrophysiologic study, 14-33 months for…
Authors
Loading...
Disopyramide may suppress accessory pathway conduction in WPW; leaves open its role versus ablation in contemporary practice.
Does disopyramide phosphate improve electrophysiologic parameters in patients with Wolff-Parkinson-White syndrome?
Absolute Event Rate: 248% vs 169%
p-value: p=<0.0001
Disopyramide prolongs refractoriness in the accessory pathway, slowing the ventricular response during atrial fibrillation in patients with Wolff-Parkinson-White syndrome.
Kerr et al. (1982) studied Wolff-Parkinson-White syndrome (n=12). Disopyramide phosphate vs. Control period (baseline) was evaluated on Shortest RR interval during atrial fibrillation (oral vs baseline) (p=<0.0001). Oral disopyramide prolonged the shortest RR interval during atrial fibrillation from 169 to 248 msec (P<0.0001) in patients with Wolff-Parkinson-White syndrome.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: